A client with bipolar disorder is prescribed valproic acid (Depakote) as part of the treatment plan. Before administering the medication, which test should be done?

Choice A reason: Blood glucose is not directly affected by valproic acid, which stabilizes mood via GABA enhancement and sodium channel inhibition. Monitoring glucose is irrelevant, as valproic acid’s primary risks involve hepatic and hematologic toxicity, not metabolic glucose dysregulation. Choice B reason: Urinalysis is not a priority for valproic acid, which primarily risks hepatotoxicity and thrombocytopenia. It enhances GABA and inhibits sodium channels, with no significant renal effects requiring routine urine monitoring, unlike drugs affecting kidney function. Choice C reason: Weight assessment is relevant for valproic acid due to potential weight gain, but it is not the priority. Hepatotoxicity, driven by valproic acid’s metabolism in the liver, poses a greater risk, necessitating liver function tests to monitor for severe hepatic damage. Choice D reason: Valproic acid, metabolized by the liver, can cause hepatotoxicity by disrupting mitochondrial function and fatty acid metabolism. Liver function tests monitor transaminases and bilirubin to detect early hepatic damage, critical before initiating treatment to ensure safe use in bipolar disorder.